{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:13:15Z","timestamp":1795158795984,"version":"4.10.3"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,10,29]],"date-time":"2003-10-29T00:00:00Z","timestamp":1067385600000},"content-version":"vor","delay-in-days":2553,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1996,11]]},"abstract":"<jats:p> <jats:bold>OBJECTIVE\u2003Verapamil has been associated with hyperprolactinaemia, but there have been no population\u2010based studies. Our objective was to determine the prevalence and degree of hyperprolactinaemia associated with verapamil in the clinical setting.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>DESIGN\u2003Observation with cross\u2010sectional and longitudinal components in the setting of an urban teaching hospital and its satellite out\u2010patient clinics.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>PATIENTS\u2003Male out\u2010patients excluding those taking other drugs known to raise PRL, renal failure and known primary hypothyroidism (1265 eligible subjects). Control subjects were drawn from eligible out\u2010patients not taking verapamil.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>MEASUREMENTS\u2003Serum PRL levels, frequency of persistent hyperprolactinaemia and total testosterone levels.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>RESULTS\u2003Prolactin levels were obtained in 449 subjects on verapamil (35.5% response rate) and 166 controls. The proportions of individuals with hyperprolactinaemia (PRL &gt;\u2003460\u2003mU\/l) were 0.085 and 0.030 in the verapamil and control groups, respectively (<jats:italic>P<\/jats:italic>\u2003=\u20030.012, \u03c7<jats:sup>2<\/jats:sup>\u2010test). The mean (\u00b1SD) serum PRL levels were 267\u2003\u00b1\u2003205 and 203\u2003\u00b1118\u2003mU\/l in the verapamil and control groups, respectively (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001, independent <jats:italic>t<\/jats:italic>\u2010test). Of the 38 patients with previously determined elevated PRL levels, follow\u2010up data were obtained in 25 (65.8%); one was found to have a pituitary adenoma and was excluded from the analysis. Fifteen of the 24 were still on verapamil (Group 1) and 14 (93.3%) continued to be hyperprolactinaemic. In 9 patients verapamil had been discontinued (Group 2) and all had normal PRL levels. Continued verapamil use was associated with persistent hyperprolactinaemia (odds ratio &gt;\u2003120, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.00001). The \u00b1\u2003SD serum testosterone levels at follow\u2010up were significantly lower in Group 1 (6.16\u2003\u00b1\u20032.52\u2003nmol\/l) than in Group 2 (9.42\u2003\u00b1\u20033.92\u2003nmol\/l, <jats:italic>P<\/jats:italic>\u2003=\u20030.029, independent <jats:italic>t<\/jats:italic>\u2010test).<\/jats:bold> <\/jats:p><jats:p> <jats:bold>CONCLUSIONS\u2003The prevalence of hyperprolactinaemia associated with verapamil use in this study of male out\u2010patients was .5% (95%\u2003Cl 5.9\u201311.1%). The persistence of hyperprolactinaemia when verapamil was continued (Group 1) and the return to normal PRL levels when verapamil was discontinued (Group 2) confirm verapamil\u2019s causal role in the development of hyperprolactinaemia. While low testosterone levels were common in both groups, testosterone levels were lower in patients on verapamil. Our data suggest that screening for hyperprolactinaemia should be considered in male patients taking verapamil.<\/jats:bold> <\/jats:p>","DOI":"10.1046\/j.1365-2265.1996.00859.x","type":"journal-article","created":{"date-parts":[[2003,11,6]],"date-time":"2003-11-06T16:07:17Z","timestamp":1068134837000},"page":"571-575","source":"Crossref","is-referenced-by-count":30,"title":["<b>Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men<\/b>"],"prefix":"10.1111","volume":"45","author":[{"given":"June H.","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dombrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun S.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fuehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,29]]},"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1996.00859.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1996.00859.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1996.00859.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T10:29:48Z","timestamp":1698402588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1996.00859.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,11]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,11]]}},"alternative-id":["10.1046\/j.1365-2265.1996.00859.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1996.00859.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,11]]}}}